Dorner T, Kaul M, Szanto A, Tseng JC, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis 2024;83:360-371.
PMID: 37932009